Kitov Pharma receives notice for anti-CEACAM1 antibody patent

Kitov had applied for a European Patent Office entitled "Humanized antibodies against CEACAM1"

picture of

Breaking News

Colorcon opens technical centre in Melbourne, Australia, to support growing pharmaceutical industry

Colorcon, a world leader in the development and supply of film coating systems and excipients, announces the opening of ...

Sun Pharma questions pandemic effects on business

Director has said performance reflects the impact of the global COVID-19 pandemic but vertical integration has ...

LGM Pharma acquires CDMO unit of Nexgen Pharma

The combined firm has all the capabilities to accelerate and optimise the new product pathway, from early R&D and ...

Identifying nitrosamines in pharmaceutical products

The TEA detector has long been an industry standard for nitrosamine analysis in food and beverages, which can also be ...

Avacta expands South Korean partnership to include COVID-19 neutralising therapy

Avacta Group has expanded its collaboration and license agreement with Daewoong Pharmaceutical and AffyXell Therapeutics

Sterling signs deal to produce potential COVID-19 drug candidate for Moleculin

Texas-based Moleculin is preparing to submit a request to the US FDA for Investigational New Drug for WP1122

Overcoming the excipient challenge with a multifunctional filler-binder

Dr Maj-Britt Cepok, Head of Business Development Pharma at BENEO, talks to Dr Kevin Robinson about trends in excipients ...

Impact Biomedical initiates research programme to solve the patent cliff

The primary cause of the patent crisis is that most techniques for modifying natural molecules to pharmaceutical grade ...

Synaffix expands collaboration with ADC Therapeutics

ADC has expanded its existing collaboration to explore additional applications of Synaffix' site-specific conjugation ...

Nitrosamines: Information for Marketing Authorisation Holders

Nitrosamine impurities have been in the regulatory spotlight since they were discovered in several blood pressure ...

How to comply with FDA-imposed nitrosamine impurity testing

The detection of nitrosamine impurities in commercially available drugs has recently prompted the US FDA to issue ...

The Lonza powder-in-capsule microdosing approach

Jeff Williamson and Ben Sahacic explain how microdosing offers a proven approach for biopharmaceutical companies to ...

GEA delivers skid-based evaporation plant to prepare a silver nitrate solution

In May 2020, GEA received a repeat order for an evaporation plant for the treatment of silver nitrate from the ...

Pfizer and BioNTech announce early positive vaccine update

Collaboration has announced results from German Phase 1/2 COVID-19 vaccine study, including first T-Cell response data